Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4052031 in Advanced or Metastatic Solid Tumors
NCT06465069Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of LY4052031 in solid tumor, urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and 7 more (4 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Recommended Phase 2 Dose at 21 days and Overall Response Rate at 48 months. Started Jul 2024; status: recruiting.
02
Drugs
LY4052031
03
Conditions
solid tumorurothelial carcinoma (UC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)esophageal cancer
Beyond the preview
Go deeper on NCT06465069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465069.